NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

ae kusterer,

Your friend hit the jackpot with methylated mesenchymal. That is the subgroup where the longest lived patients from the earlier trial came from but which traditionally fair poorly because of the very aggressive mesenchymal subtype. If ANYONE thinks that this treatment will not be APPROVED based just on this alone after the SAP has been fitted to prove this correlation, they are very, very, very sadly mistaken. The original parameters did not test for this subgroup because the subgroups were not well defined when this ADAPTIVE trial began. This SAP will bring everything and the kitchen sink to PROVE beyond a shadow of a doubt where the correlations to response come from in nearly all if not all cases.

No one talks much about methylated mesenchymal anymore because some research suggested that methylated came almost exclusively from proneural subtype. This is just a plain wrong understanding. Those pseudo progression spots are probably the areas of cancer cell clusters that were created by transition to mesenchymal phenotype as exozomes and mesenchymally mobilized cancer cells offered exposed targets to hit by circulating DCs and educated and unimpeded T-cells. Your friend has every reason to believe that he will be a Brad Silver, Kat and Mr. Powers type story. Best wishes.